Scientific article
Open access

EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer

Published inBritish journal of cancer, vol. 88, no. 5, p. 648-653
Publication date2003

Cancer of the colon and rectum is one of the most frequent malignancies both in the US and Europe. Standard palliative therapy is based on 5-fluorouracil/folinic acid combinations, with or without oxaliplatin or irinotecan, given intravenously. Oral medication has the advantage of greater patient convenience and acceptance and potential cost savings. S-1 is a new oral fluorinated pyrimidine derivative. In a nonrandomized phase II study, patients with advanced/metastatic colorectal cancer were treated with S-1 at 40 mg m-2 b.i.d. for 28 consecutive days, repeated every 5 weeks, but by amendment the dose was reduced to 35 mg m-2 during the study because of a higher than expected number of severe adverse drug reactions. In total 47 patients with colorectal cancer were included. In the 37 evaluable patients there were nine partial responses (24%), 17 stable diseases (46%) and 11 patients had progressive disease (30%). Diarrhoea occurred frequently and was often severe: in the 40 and 35 mg m-2 group, respectively, 38 and 35% of the patients experienced grade 3-4 diarrhoea. The other toxicities were limited and manageable. S-1 is active in advanced colorectal cancer, but in order to establish a safer dose the drug should be subject to further investigations.

  • Aged
  • Antimetabolites, Antineoplastic/adverse effects/therapeutic use
  • Colorectal Neoplasms/drug therapy/pathology
  • Drug Combinations
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Oxonic Acid/adverse effects/therapeutic use
  • Pyridines/adverse effects/therapeutic use
  • Tegafur/adverse effects/therapeutic use
  • Treatment Outcome
Citation (ISO format)
VAN DEN BRANDE, J et al. EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. In: British journal of cancer, 2003, vol. 88, n° 5, p. 648–653. doi: 10.1038/sj.bjc.6600781
Main files (1)
Article (Published version)
ISSN of the journal0007-0920

Technical informations

Creation01/19/2015 4:19:00 PM
First validation01/19/2015 4:19:00 PM
Update time03/14/2023 10:44:40 PM
Status update03/14/2023 10:44:39 PM
Last indexation10/18/2023 9:42:45 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack